Zymeworks Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Zymeworks Inc. - overview
Established
2003
Location
Vancouver, BC, Canada
Primary Industry
Biotechnology
About
Founded in 2003 and headquartered in Vancouver, Canada, Zymeworks Inc. is a biotechnology firm dedicated to developing innovative therapeutics for serious health conditions, focusing primarily on oncology, inflammation, and autoimmune diseases through advanced antibody technology. Zymeworks Inc. specializes in biopharmaceutical development, particularly in the creation of multifunctional therapeutics.
The company has not reported any significant pivots in business strategy. Kenneth Galbraith serves as the current CEO of Zymeworks Inc.. The company develops novel, multifunctional therapeutics specifically designed to address healthcare needs in oncology, inflammation, and autoimmune diseases. Its flagship product, zanidatamab, is a HER2-targeted bispecific antibody utilizing the proprietary Azymetric™ technology, aimed at treating adults with unresectable or metastatic HER2-positive biliary tract cancer.
The drug has received accelerated approval from the U. S. FDA and conditional approval from China's NMPA. Zymeworks Inc.
collaborates with global biopharmaceutical companies, granting exclusive rights for the development and commercialization of zanidatamab in various regions, including the United States and China, with ongoing clinical trials in the European Union. In the most recent fiscal year 2022, Zymeworks reported revenue of USD 412. 48 mn and an EBITDA of USD 142. 53 mn.
The company generates revenue primarily through strategic partnerships and exclusive licensing agreements with other biopharmaceutical firms, where partners commercialize Zymeworks' products in specific territories. These agreements typically involve upfront payments, milestone payments for regulatory achievements, and royalties on sales. Zymeworks intends to utilize the recent funding towards advancing the clinical development of its lead therapeutic candidates, ZW25 and ZW33, which are scheduled to enter clinical trials later this year. The company is also targeting expansion into new geographic markets to enhance its global presence.
In March 2026, Royalty Pharma agreed to issue a USD 250 million non-recourse royalty-backed notes to Zymeworks Inc. with repayments due from 30% of worldwide tiered royalties on its product, Ziihera. The financing will enhance the company's balance sheet with non-dilutive capital and back its repurchase program, fund potential strategic acquisitions.
Current Investors
EcoR1 Capital, CTI Life Sciences, Advanced Biotechnologies Venture Fund
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.zymeworks.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Zymeworks Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Announced | Zymeworks Inc. | - | ||||||||
| PIPE | Completed | Zymeworks Inc. | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.